Efficacy and Safety of Activated Recombinant Human Factor VII in Severely Injured Trauma Patients
Status:
Completed
Trial end date:
2003-10-01
Target enrollment:
Participant gender:
Summary
This trial is conducted in Africa, Asia, Europe, Oceania and North America. The aim of this
trial is to evaluate the efficacy of activated recombinant human factor VII given in
conjunction with standard therapy in the treatment of massive bleeding in subjects with
severe blunt and/or penetrating trauma injury.